about
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules,...
Read More
32.80
-0.61
(-1.83%)
182.2K
XNAS Volume
XNAS 18 Jun, 2026 5:30 PM (EDT)
Board Meeting
The next board meeting for Pharvaris NV is on 26 Jun 2026 for the purpose of Pharvaris NV Annual General Meeting for 2026
See details
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Pharvaris NV Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..